NHS Clinical Safety · AI Health Products

The infrastructure layer that makes NHS digital health work

Sapphire Digital Health Advisory bridges the gap between clinical authority and digital innovation — advising health tech companies, building AI-powered platforms, and exporting NHS-grade governance globally.

£4.8Bn+UK Addressable Market
+750%Rise in ADHD Tribunals
4International Markets
SDHA
What We Do

Clinical authority meets digital innovation

We are one of the few firms where the same practising NHS physician who signs Clinical Safety Case Reports also builds the AI products — combining regulatory depth with clinical authority.

Clinical Safety Officer Outsourcing

Fully outsourced DCB0129/DCB0160 Clinical Safety Officer service for digital health organisations that need NHS-qualified clinical governance without the overhead of a full-time appointment.

Learn more →
clinical.safety@sapphiredigitalhealth.co.uk

DTAC Compliance & Advisory

End-to-end Digital Technology Assessment Criteria support — from gap analysis and clinical safety case development through to successful NHS procurement submission.

Learn more →
consulting@sapphiredigitalhealth.co.uk

Allo Neurodiversity Platform

Three-module AI-powered platform: Allo Workplace for employers, Allo Clinical for adult assessment, and Allo Paediatrics for children aged 5–17. The only full-suite ND platform built by a practising NHS clinician.

Explore Allo →
info@sapphiredigitalhealth.co.uk

Clinical Safety Retainer

Ongoing embedded CSO coverage for digital health product teams. Continuous safety case maintenance, DCB0129 compliance, and clinical governance as your product evolves post-launch.

Learn more →
clinical.safety@sapphiredigitalhealth.co.uk

International Advisory

NHS-grade clinical safety advisory for health organisations in Nigeria, the GCC, India, and Southeast Asia — bringing world-class governance standards to rapidly growing digital health markets.

Explore →
consulting@sapphiredigitalhealth.co.uk

Digital Clinical Safety Audit

Comprehensive gap analysis of your digital health product's clinical safety posture — with a remediation roadmap, board-ready reporting, and prioritised action plan for DTAC readiness.

Learn more →
clinical.safety@sapphiredigitalhealth.co.uk
Why SDHA

Built from inside the system

Clinical Authority

Our founder is a GMC-registered, practising NHS physician. Every clinical safety case report carries the signature of someone who understands the clinical reality — not just the regulatory framework.

Regulatory Depth

DCB0129 and DCB0160 qualified. Deep expertise in DTAC, MHRA SaMD classification, NHS procurement pathways, and the evolving UK AI regulation landscape.

Builder Mindset

We don't just advise — we build. The Allo platform was developed using the same regulatory intelligence we apply to client work, creating a feedback loop between practice and product.

Ready to begin

Start with a Discovery Call

Every engagement begins with a complimentary 45-minute discovery call. We'll understand your product, your regulatory position, and where we can add the most value — with no commitment required.

Our Story

One organisation.
Two disciplines.
One mission.

Sapphire Digital Health Advisory was founded on a singular insight: that the gap between clinical excellence and digital innovation in the NHS is not a technology problem — it is a translation problem.

Our Foundation

Why SDHA exists

Too many genuinely good digital health products fail at the NHS procurement stage — not because they don't work, but because they lack a DCB0129-compliant Clinical Safety Case signed by a qualified Clinical Safety Officer. That regulatory gap represents millions in wasted investment and — more importantly — delayed access to tools that could transform patient care.

Dr Jide Idowu founded SDHA having sat on both sides of the NHS procurement process: as a practising clinician assessing digital health submissions, and as a digital health strategist building the products. That dual vantage point is what SDHA was built to deploy.

"I've sat in NHS procurement meetings as the clinician reviewing digital health submissions. I've seen how many good products fail — not because of the technology, but because of the paperwork they didn't know was required. That knowledge shouldn't be locked inside the system."

— Dr Jide Idowu, CEO & Clinical Safety Officer

Our Dual Model

SDHA operates as both an advisory practice and a product company. Our advisory work — CSO outsourcing, DTAC compliance, clinical safety audits, and international advisory — generates the revenue and the regulatory intelligence that feeds into our product development. Allo, our neurodevelopmental platform, is built using the same clinical governance standards we enforce for our advisory clients.

This creates a virtuous cycle: our product experience makes us better advisors; our advisory expertise makes our products more defensible. Neither would be possible without the other.

Our Values

Clinical firstNo digital health product should compromise patient safety. Every recommendation we make is grounded in clinical reality, not just regulatory boxes ticked.
TransparencyWe tell clients what they need to hear, not what they want to hear. Our advisory is honest about regulatory risk and realistic about timelines.
EquityNeurodiversity affects 15% of the population. NHS waiting lists fail women, AFAB adults, and children disproportionately. Allo is built to correct that.
PrecisionWe do fewer things and do them better. We do not accept engagements where we cannot add genuine value.

Dr Jide Idowu

CEO & Clinical Safety Officer

  • MBBS — Primary Care Physician, NHS
  • GMC Registered Practitioner
  • DCB0129 / DCB0160 Qualified CSO
  • PG Certificate — Neurodiversity
  • Clinical Governance, NHS Trust
  • Digital Health Strategist & AI Builder
  • Associate Specialist, NHS
  • International Health Advisory — Nigeria, GCC

First client signed May 2026. Dual-market NHS and Nigeria NDPA compliance advisory. Built the Allo 3-module neurodevelopmental platform.

Clinical Services

Regulatory expertise
that opens doors

From DTAC submission to embedded CSO coverage, our services are designed to take digital health companies from regulatory uncertainty to NHS procurement readiness — without the complexity of building in-house capability.

Clinical Safety

Clinical Safety Officer Outsourcing

Every digital health product placed on the NHS market requires a DCB0129-compliant Clinical Safety Case and a qualified Clinical Safety Officer to sign it. Most digital health companies — particularly early-stage startups and international companies entering the UK market — do not have a GMC-registered, DCB0129-qualified physician on their team.

SDHA provides a fully outsourced CSO service that gives your organisation the clinical governance it needs without the cost and complexity of a permanent senior clinical appointment. Dr Idowu acts as your named Clinical Safety Officer, taking legal and professional responsibility for your clinical safety case.

This is not a rubber-stamp service. Every engagement begins with a thorough review of your product's intended purpose, clinical workflow, and risk profile. We will tell you what needs to be remediated before we sign anything.

  • Named DCB0129/DCB0160 qualified Clinical Safety Officer for your product
  • Clinical Safety Case development and maintenance
  • Hazard Log management and clinical risk assessment
  • Clinical Safety Management System (CSMS) establishment
  • Incident management and safety reporting protocols
  • Clinical validation oversight and sign-off
  • Interface with NHS procurement assessors on your behalf
  • Regulatory change monitoring (DCB standard updates)
DCB0129DCB0160CSMSNHS Procurement

Enquire about CSO Services

clinical.safety@sapphiredigitalhealth.co.uk
cso@sapphiredigitalhealth.co.uk
(+44) 07376 309 553
DTAC Compliance

DTAC Compliance & NHS Procurement Advisory

The Digital Technology Assessment Criteria (DTAC) is the NHS's gateway for digital health products. Meeting DTAC requirements across clinical safety, data protection, interoperability, usability, and accessibility is a complex, multi-disciplinary process. Failure to meet DTAC standards is the single most common reason good digital health products do not reach NHS patients.

SDHA provides end-to-end DTAC advisory — from initial gap analysis to submission support and post-assessment remediation. Our clinical background means we approach DTAC not as a compliance checklist, but as a genuine quality assurance framework that protects patients.

  • DTAC gap analysis against all five criteria domains
  • Clinical Safety domain — DCB0129 compliance, hazard log, CSMS
  • Data Protection domain — DPIA, UK GDPR compliance, ICO registration
  • Technical Security domain — Cyber Essentials, penetration testing guidance
  • Interoperability domain — FHIR R4, NHS login, NHS number integration
  • Usability & Accessibility domain — WCAG 2.1 AA, NHS design principles
  • Submission preparation and NHS assessor liaison
  • Remediation roadmap and re-submission support
DTACNHS App LibraryFHIR R4UK GDPR

Enquire about DTAC

consulting@sapphiredigitalhealth.co.uk
info@sapphiredigitalhealth.co.uk
(+44) 07376 309 553
Ongoing Coverage

Clinical Safety Retainer

Achieving initial DTAC compliance is not the end of the regulatory journey — it is the beginning. As your product evolves, as new features are added, as AI models are updated, your clinical safety case must be maintained, updated, and re-validated. The DCB0129 standard requires ongoing safety management, not a one-time document.

SDHA's Clinical Safety Retainer provides continuous embedded CSO coverage for digital health product teams. Dr Idowu functions as an integrated member of your governance framework — attending relevant product reviews, maintaining the hazard log, signing off on clinical safety amendments, and ensuring your product remains in continuous compliance as it scales.

  • Monthly clinical safety review meetings with your product team
  • Continuous hazard log maintenance and review
  • Clinical sign-off for all significant product changes
  • Incident triage and clinical safety event reporting
  • Post-market clinical follow-up for SaMD products
  • Regulatory horizon scanning — MHRA, NHS, NICE updates
  • Board-level clinical safety reporting
  • Priority response for clinical safety incidents

Enquire about Retainer

clinical.safety@sapphiredigitalhealth.co.uk
ceo@sapphiredigitalhealth.co.uk
(+44) 07376 309 553
Audit

Digital Clinical Safety Audit

Before committing to a full DTAC submission or CSO engagement, many organisations benefit from an independent, structured assessment of where they currently stand — what their clinical safety strengths are, what the material gaps are, and what the realistic path to compliance looks like.

SDHA's Digital Clinical Safety Audit is a focused, time-bounded engagement that delivers a clear picture of your regulatory position, a prioritised gap-closure roadmap, and a board-ready report suitable for presenting to investors, NHS Trust governance committees, or ICB procurement panels.

  • Structured review of existing clinical safety documentation
  • Hazard identification and risk classification assessment
  • CSMS adequacy review against DCB0129 requirements
  • Clinical workflow and intended use analysis
  • Data protection and GDPR posture review
  • Prioritised remediation roadmap with timeline estimates
  • Board-ready clinical safety audit report
  • Verbal debrief with CEO, CTO, and clinical leads

Enquire about Audit

clinical.safety@sapphiredigitalhealth.co.uk
consulting@sapphiredigitalhealth.co.uk
(+44) 07376 309 553
Allo Platform · Neurodiversity

The neurodevelopmental platform built from inside the NHS

Allo is a suite of clinically-governed neurodevelopmental tools built to change three things: how the workplace supports neurodivergent employees, how adults access assessment, and how children are identified before the system loses them. Each module addresses a different dimension of the same failure — and each carries the clinical safety standards of a practising NHS physician who has seen that failure up close.

Allo Workplace
Allo Clinical
Allo Paediatrics
Occupational Health · Employer Platform

Allo Workplace

"Employment tribunals citing ADHD and neurodevelopmental conditions have risen by over 750% since 2020. Most employers are unprepared — not from indifference, but from the absence of a clinically-grounded process. Allo Workplace exists to close that gap."

Neurodiversity in the workplace is one of the most consequential — and most poorly managed — occupational health challenges of our time. Fifteen million people in the UK are neurodivergent. Most are in employment. The majority are unsupported, misunderstood, or managing entirely alone. The cost to employers — in tribunal risk, lost productivity, retention, and reputational damage — is measurable and growing.

Allo Workplace was built on a simple clinical premise: that functional need, not formal diagnosis, is the correct basis for workplace support. It introduces a structured occupational health assessment process — grounded in Equality Act 2010 principles — that enables employers to meet their legal duties and employees to be genuinely heard, without requiring either party to navigate the broken NHS diagnostic pathway first.

The impact is two-directional. For the neurodivergent employee, it creates a voice: a clinically-designed framework that captures their functional reality at work in their own words, generates a professional occupational health-style report, and routes that report to the people who can act on it. For the employer, it creates the documented, legally-defensible process that transforms a potential liability into a demonstrable duty of care.

Clinical safety is built into every layer. The assessment is designed by a GMC-registered NHS physician to produce documentation suitable for occupational health review, HR decision-making, and — if necessary — Employment Tribunal scrutiny. Every output carries embedded safeguards against diagnostic overreach, data misuse, and legal exposure.

Allo Workplace is in active development. If you represent an NHS Trust, an employer, an occupational health provider, or an employment law firm and would like to discuss early access, integration, or partnership — we would like to hear from you.

What Allo Workplace promises

For neurodivergent employees

A clinician-designed process that captures how their neurodivergent profile actually affects their work — in their own words, without diagnostic gatekeeping, and with full control over who sees their information.

For HR & occupational health

Structured, occupational health-grade functional reports — generated without requiring a clinical appointment — that provide the documented evidence base for reasonable adjustment decisions.

For employers navigating legal risk

A proactive, auditable compliance process aligned to the Equality Act 2010 and ACAS 2025 guidance — replacing informal, inconsistent approaches with a clinically-grounded, legally-defensible standard.

For the neurodiversity ecosystem

The first workplace tool built from the perspective of a practising NHS clinician who has seen the consequences of the diagnostic gap — and designed a system that does not wait for a diagnosis to act.

Clinical safety embedded

Every report generated by Allo Workplace passes through a non-diagnostic language filter, a privacy gate, and a clinical governance review layer — designed by the same NHS physician who signs clinical safety cases for digital health products.

Adult Assessment · SaMD in Development

Allo Clinical

"180,000 adults are currently waiting 2–5 years for a neurodevelopmental assessment on the NHS. Allo Clinical is being built to change what happens before the clinician walks in the room — and after."

The neurodevelopmental assessment crisis is not primarily a funding problem. It is a system design problem. Specialist clinician time is the scarcest resource in the pathway — and today, far too much of it is consumed by structured history-taking that could be done before the appointment begins. A consultant psychiatrist or clinical psychologist spending the first 40 minutes of a consultation gathering information that the patient has answered many times before is a systemic inefficiency that costs the NHS millions and costs patients years.

Allo Clinical is being developed to address this directly. It is an AI-powered neurodevelopmental assessment support tool — built to be used before the clinical consultation — that collates, structures, and synthesises the patient's functional profile across multiple neurodevelopmental domains. By the time the clinician opens the consultation, they have in front of them a comprehensive, evidence-based profile rather than a blank page. What previously required multiple appointments can begin with the depth and breadth of a structured pre-assessment already complete.

Addressing the biases that have hidden millions from diagnosis

The science of neurodevelopmental under-diagnosis is well-established. Women are diagnosed with ADHD on average seven years later than men. ASD is identified in boys at four times the rate of girls — not because it is rarer, but because the behavioural presentations differ and the tools were validated predominantly on male populations. Cultural and socioeconomic factors create further diagnostic shadows. Allo Clinical is being engineered from the ground up to detect and correct for these biases — not as an afterthought, but as a core design principle.

The platform incorporates proprietary correction methodology — developed by a practising NHS clinician with deep expertise in neurodevelopmental under-diagnosis — that adjusts for the masking behaviours, internalised presentations, and cultural factors that cause standard assessment tools to miss the patients who need help most. The precise mechanism of this correction is protected intellectual property. What we can say is that it is grounded in the peer-reviewed masking literature and validated against real-world diagnostic data.

Beyond bias correction, Allo Clinical integrates established, clinically validated assessment instruments — the same tools used by specialist clinicians in NHS and private practice — synthesising multi-source data in a way that no single tool has previously achieved in one consultation-ready package.

Clinical safety is not a feature — it is the foundation

Allo Clinical is being built to MHRA Software as a Medical Device standards from day one. The clinical safety architecture — designed by the same DCB0129-qualified physician who leads SDHA — includes multi-tier safety classification, mandatory clinician review gates, and a regulatory compliance layer that means every output is designed to support, never to replace, the diagnosing clinician's professional judgement. This is not an app that tells people they have ADHD. It is a clinical instrument that gives the clinician more to work with in the time they have.

Allo Clinical is currently in development. We are in active dialogue with NHS Right to Choose providers, ICBs, and clinical psychology practices about the design and deployment pathway. If you are a clinician, a commissioner, or an organisation interested in early access or research collaboration — please reach out.

The clinical promise

Shorter consultations. Deeper outcomes.

By completing structured pre-assessment before the clinician's time begins, Allo Clinical is designed to compress the information-gathering phase of neurodevelopmental consultation — giving specialist clinicians the capacity to see more patients, and giving each patient a richer, more evidence-informed assessment than the current pathway allows.

Built around the clinician — not around the technology

Allo Clinical generates a structured clinical synthesis for the diagnosing clinician. It does not generate a diagnosis. It does not replace clinical judgement. It makes the clinician's task more precise, more complete, and more defensible — in significantly less time.

Correcting the bias the system built in

The tools currently used in NHS assessment were largely validated on populations that do not reflect the full diversity of neurodivergent experience. Allo Clinical is being designed to see the patients those tools miss — particularly women, AFAB adults, and individuals whose presentations do not match the textbook profile.

Multi-condition, not single-condition

Neurodevelopmental conditions co-occur at rates of up to 70%. Assessing for ADHD alone misses the ASD beneath. Assessing for ASD alone misses the Dyslexia alongside it. Allo Clinical is designed for the clinical reality — multi-condition differential, not single-condition confirmation.

Regulatory commitment

Allo Clinical is being engineered to MHRA UKCA SaMD standards, DCB0129 clinical safety requirements, and NHS Digital Technology Assessment Criteria — from the first line of code. Clinical safety is not retrofitted. It is designed in.

Children & Young People · CAMHS · Ages 5–17

Allo Paediatrics

"Over 120,000 children are currently waiting for CAMHS assessment. 60% of referrals are rejected before they begin. Behind every one of those numbers is a child in school, at home, and in life — without the understanding they need to thrive. Allo Paediatrics is being built for them."

The CAMHS neurodevelopmental crisis is a generational failure. Children are being identified as struggling by their teachers and parents — sometimes years before they receive any clinical assessment — while they fall further behind academically, socially, and emotionally. The gap between identification and assessment is not measured in weeks. It is measured in years. In missed EHCPs. In exclusions. In mental health crises that could have been prevented with earlier support.

Allo Paediatrics is being developed to create a structured, clinically-supervised pathway between identification and assessment — reducing the burden on an overstretched CAMHS system by ensuring that, when a specialist clinician finally sees a child, they are not starting from zero. They are starting from a comprehensive, multi-informant, clinically organised profile of that child's neurodevelopmental presentation, synthesised from the voices of the people who know them best: the child themselves, their parents or carers, and their teachers.

Why children are missed — and how Allo Paediatrics addresses it

Neurodevelopmental conditions present differently in children than in adults, and differently again across age bands, genders, and cultural contexts. The diagnostic tools in routine CAMHS use were not designed for the full spectrum of presentations. Girls with ADHD are systematically under-identified because their presentations are predominantly inattentive and internalised rather than hyperactive and externalised. Children from under-represented ethnic communities are less likely to receive timely referral. Children who have learned to mask their difficulties — often the most able, and therefore the most underserved — are routinely missed entirely.

Allo Paediatrics is being designed to surface these hidden presentations — not by replacing clinical judgement, but by gathering richer, more representative information than any single assessment appointment can provide. The platform combines multiple sources of structured observational data — from the child, from home, and from school — and synthesises them through a clinically-validated framework that the CAMHS clinician can interrogate, challenge, and act upon.

The child's voice is at the centre of this. Children are not just the subject of neurodevelopmental assessment — they are participants in it. Allo Paediatrics is being designed so that children aged 5 to 17 can contribute meaningfully to their own profile, in age-appropriate ways, with full safeguarding oversight embedded at every point.

Safeguarding and clinical safety are non-negotiable

Allo Paediatrics is being built with the understanding that a platform touching children's mental health and neurodevelopmental data carries the highest possible clinical responsibility. The safeguarding architecture, the clinical safety framework, and the data governance model are all being designed to the standard expected of a regulated medical device — because that is exactly what this is. No output is generated without clinician review. No safeguarding signal is ignored. No data is processed without appropriate consent and governance. This is not a self-referral app. It is a clinical support tool, designed for use within — and accountable to — clinical systems.

Allo Paediatrics is in development. We are seeking partnerships with CAMHS services, NHS Right to Choose paediatric providers, local authorities, and SENCO networks to co-develop and pilot the platform. If you work in this space and share this vision — we would like to hear from you.

The paediatric promise

For children who have been waiting

A clinically-designed process that gathers a child's neurodevelopmental profile before the clinical appointment begins — so that specialist time is spent on clinical decision-making rather than structured history-taking. The consultation that used to take three appointments can begin with far greater depth.

For parents who have been fighting

A structured way to contribute their observations — the developmental history, the home behaviours, the patterns they have noticed for years — in a format that is clinically organised and directly useful to the clinician who will ultimately assess their child.

For SENCOs and schools

A pathway to contribute what they observe in the classroom to the clinical record — closing the gap between educational identification and clinical assessment that currently leaves many children unrecognised for years.

For CAMHS services under pressure

A tool that enables smarter triage, richer first appointments, and a structured pre-assessment record that means no clinician ever has to start from scratch — even with a child who has been waiting two years to be seen.

Designed to the highest clinical standard

Every aspect of Allo Paediatrics — from the assessment questions to the data architecture — is being built under the clinical governance of a DCB0129-qualified NHS physician, with safeguarding, MHRA SaMD compliance, and children's rights at the centre of every design decision.

Interested in partnering with Allo?

NHS Trusts, ICBs, independent Right to Choose providers, and employers — all three Allo modules are available for integration, white-labelling, and NHS procurement. Contact us to discuss.

info@sapphiredigitalhealth.co.uk
Global Advisory

NHS-grade governance,
exported globally

Digital health is growing fastest in markets where regulatory infrastructure is still being established. SDHA brings NHS-standard clinical safety governance to Nigeria, the GCC, India, and Southeast Asia — where there is no equivalent expertise on the ground.

Our Markets

Four markets. One standard.

We do not adapt our standards to each market — we bring NHS-grade clinical governance to each context, adapted to the local regulatory framework.

🇳🇬 Nigeria

Nigeria's Federal Ministry of Health is actively building a digital health regulatory framework, including the National Digital Health Policy and the NDPA (Nigeria Data Protection Act). SDHA is advising on NHS-standard clinical safety for Nigerian health tech organisations and international companies entering the Nigerian market.

  • Clinical safety framework design aligned to NDPA and FMoH policy
  • Digital health product safety assessment
  • NHS-to-Nigeria regulatory translation advisory
  • Health data governance and NDPA compliance
  • Telemedicine and e-health platform advisory

🇦🇪 Gulf Cooperation Council

With $20Bn+ in planned digital health investment across Saudi Arabia, UAE, Qatar, and Kuwait, the GCC is the fastest-growing digital health market outside East Asia. SDHA advises GCC health organisations and international companies entering the GCC on clinical safety standards aligned to SFDA, MOH UAE, and CDER frameworks.

  • SFDA (Saudi FDA) clinical safety advisory
  • UAE Ministry of Health regulatory alignment
  • AI health product governance for GCC deployment
  • Clinical safety case development for GCC procurement
  • NHS-GCC health system comparison and gap analysis

🇮🇳 India

India's digital health market is growing at 39% annually, driven by the Ayushman Bharat Digital Mission (ABDM) and a rapidly expanding private health tech sector. SDHA advises Indian health tech companies on international market entry — particularly NHS and GCC regulatory requirements — and Indian health organisations on NHS-standard clinical governance.

  • ABDM-aligned clinical safety advisory
  • NHS market entry regulatory pathway for Indian health tech
  • CDSCO (India) medical device regulatory advisory
  • International investor-readiness clinical governance
  • Telemedicine and AI diagnostic platform advisory

🌏 Southeast Asia & Beyond

Singapore, Malaysia, Thailand, and Indonesia are developing sophisticated digital health regulatory frameworks. SDHA provides advisory to organisations navigating multi-jurisdictional deployment — helping health tech companies achieve clinical safety standards acceptable across multiple regulatory environments simultaneously.

  • HSA Singapore SaMD regulatory advisory
  • Multi-jurisdictional clinical safety framework design
  • WHO digital health standards alignment
  • Cross-border health data governance
  • International investor due diligence clinical safety review
First-Mover Position

No direct competitor on the ground

SDHA is the only organisation combining GMC-registered clinical authority with NHS-standard regulatory expertise and active presence across all four international markets. There is no equivalent service in Nigeria, the GCC, India, or Southeast Asia — which is precisely the opportunity.

Our international advisory is not a separate product — it is the same clinical rigour we apply to our NHS work, translated into each regulatory context with the respect and precision that each market deserves.

International Enquiries

consulting@sapphiredigitalhealth.co.uk
ceo@sapphiredigitalhealth.co.uk
(+44) 07376 309 553
Monthly Column

The Sapphire Review

Digital health intelligence for clinicians, innovators, and policymakers. From NHS procurement reform to global health technology — authored by Dr Jide Idowu and the SDHA clinical advisory team.

NHS
NHS Reform · June 2026

Why DTAC Is the Most Important Three Letters in NHS Digital Health — and Why Most Founders Don't Know What It Means

The Digital Technology Assessment Criteria has been the NHS's gateway for digital health products since 2021. Five years on, it remains one of the most misunderstood regulatory frameworks in UK health technology. Dr Jide Idowu explains what DTAC actually requires, why so many good products fail it, and what the NHS needs to change to unlock the full potential of its digital health pipeline.

Dr Jide Idowu·12 min read·DTAC, NHS, Clinical Safety
Neurodiversity · May 2026

The Gender Gap in ADHD Diagnosis: How Masking Has Hidden 3 Million Women from the NHS

ADHD affects approximately the same proportion of women as men — yet women are diagnosed, on average, 7 years later. The reason is masking: the learned behavioural suppression of neurodivergent traits that makes women appear neurotypical in clinical settings. Dr Idowu examines the science, the consequences, and what Allo Clinical's Composite Masking Index is designed to do about it.

Dr Jide Idowu·15 min read·ADHD, Women's Health, Diagnosis
AI & Regulation · April 2026

The MHRA's AI Guidance Is Here. What Does It Actually Mean for Health Tech Founders?

In February 2025, MHRA published updated Digital Mental Health Technology guidance that significantly shifted the SaMD qualification landscape. Many AI health products that previously operated in a regulatory grey zone now face a clear decision: classify as a medical device, or rigorously document why they do not. We break down the guidance, the two-part test, and what founders need to do now.

Dr Jide Idowu·10 min read·MHRA, AI, SaMD, Regulation
Global Health · March 2026

Nigeria's Digital Health Revolution: Why West Africa Is About to Leapfrog Europe in Health Technology Adoption

Nigeria has 220 million people, a rapidly expanding private health sector, and a federal government committed to digital health transformation. It also has a fraction of the clinical workforce it needs. The result is the fastest-growing opportunity for digital health platforms in the world — and an acute need for the clinical safety governance standards that will make adoption safe. Dr Idowu writes from the ground.

Dr Jide Idowu·14 min read·Nigeria, Global Health, Digital Health
Workforce · February 2026

750% and Rising: The ADHD Employment Tribunal Crisis That Every HR Director Needs to Read

Employment tribunal cases citing ADHD have risen by over 750% since 2020. The Equality Act 2010 requires employers to make reasonable adjustments for employees with disabilities — including neurodivergent conditions — but fewer than 28% of HR teams report feeling confident in their legal obligations. This piece examines the data, the legal framework, and what employers must do before they face a claim.

Dr Jide Idowu·11 min read·ADHD, Employment Law, HR
CAMHS · January 2026

120,000 Children Waiting. The CAMHS Crisis Is Not a Funding Problem — It's a System Architecture Problem

The CAMHS backlog is not new. What is new is the growing body of evidence that the bottleneck is not funding — it is system design. CAMHS was built for a world in which specialist clinician time was the only pathway to assessment. Digital pre-assessment platforms can fundamentally restructure that pathway — but only if they are built with the clinical rigour the system demands. We examine what good looks like.

Dr Jide Idowu·13 min read·CAMHS, Children, NHS, Mental Health
About the Column

The Sapphire Review publishes monthly, authored by Dr Jide Idowu and the SDHA clinical team. We write for founders, clinicians, policymakers, and investors — anyone serious about the future of digital health.

Subscribe for monthly delivery

Coming Next

The NHS Right to Choose Pathway: A Founder's Complete Guide

Everything a digital health company needs to know about positioning their assessment platform for NHS Right to Choose commissioning — from regulatory requirements to commercial model.

July 2026
GCC Edition

Saudi Vision 2030 & Digital Health: The Regulatory Landscape Every International Company Needs to Understand

A deep dive into SFDA classification, MOH Saudi digital health policy, and what NHS-standard governance means in a GCC context.

August 2026
Policy

The Mandler Review's Missing Chapter: What the NHS AI Strategy Gets Wrong About Clinical Safety

A critical reading of NHS AI governance policy — and what a genuinely clinician-led AI strategy would look like.

September 2026
Research

Masking Across Cultures: Is the Gender Bias in ND Diagnosis Worse Outside the UK?

New cross-national data on ADHD and ASD diagnosis rates by gender — and what it means for global neurodevelopmental health equity.

October 2026
Write for The Sapphire Review

We accept contributions from clinicians, health tech founders, policymakers, and researchers. Submissions open quarterly.

info@sapphiredigitalhealth.co.uk
Get in Touch

Every engagement
begins with a
conversation

Whether you're a digital health startup, an NHS Trust, an international health organisation, or an employer navigating neurodiversity in the workplace — we'd like to hear from you. All enquiries receive a response within one business day.

Send us a message

By submitting, you agree to our privacy policy. We will not share your information with third parties. All enquiries are treated as confidential.

Contact information

General Enquiries

info@sapphiredigitalhealth.co.uk

Consulting & Advisory

consulting@sapphiredigitalhealth.co.uk

Clinical Safety Services

clinical.safety@sapphiredigitalhealth.co.uk

Dr Jide Idowu — Direct

drjide@sapphiredigitalhealth.co.uk

CEO Office

ceo@sapphiredigitalhealth.co.uk

CSO Office

cso@sapphiredigitalhealth.co.uk

Phone & WhatsApp

(+44) 07376 309 553

Book a Discovery Call

Every engagement begins with a complimentary 45-minute discovery call. No commitment, no sales pitch — just an honest conversation about where we can add value.